# A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

> **NCT05245656** · PHASE2 · RECRUITING · sponsor: **Kim, Seok Jin** · enrollment: 90 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** RB/RBAC alternating
- **DRUG:** RB

## Key facts

- **NCT ID:** NCT05245656
- **Lead sponsor:** Kim, Seok Jin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-18
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245656, "A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05245656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*